Objective To evaluate the detection rate,accuracy rate,and false negative rate of axillary sentinel lymph node biopsy (SLNB) after neoadjuvant chemistry (NAC) in axillary lymph node (ALN) clinical node negative (cN0) patients examined by physical examination,breast ultrasound,and breast magnetic resonance imaging (MRI),and discuss the feasibility of ASLNB after NAC.Methods Seventy-four cases of breast cancer admitted to the Department of Surgery Oncology,Provincial Clinical Institute,Fujian Medical University from August 2013 to July 2016 were enrolled in the study for retrospective analysis.All of the patients receiving NAC were divided into three groups according to the results of physical examination,breast ultrasound,and MRI.There were 55 cN0 cases judged by physical examination and breast ultrasound (group A),50 cyN0 cases by additional breast MRI (group B),and 24 clinical node positive (cN+) cases by all the three examination techniques (group C).Results In group A,the clinical remission rate of ALN was 74.3%,and the successful rate,accuracy rate,and false negative rate of ASLNB were 100%,92.7%,and 9.7%,respectively.In group B,the above indicators were 67.6%,100%,94.0%,and 7.8%,respectively.The cN+ patients in group C were given axillary lymph node dissection (ALND).The false negative rate of ASLNB had no significant difference (P>0.05) between group A and group B.Conclusion SLNB can replace ALND for the patients whose ALN transformed to cN0 from cN+ after NAC by physical examination and breast ultrasound.The false negative rate can be further decreased with additional MRI.MRI can be used to judge ALN in breast cancer patients after NAC.
ZHANG Hui
,
LIN Mengbo
,
WANG Jinsi
,
CHEN Xiaogeng
,
FAN Yuezu
. Effect of neoadjuvant chemotherapy on sentinel lymph node in breast cancer patients[J]. Surgical Research and New Technique, 2017
, 6(4)
: 235
-238
.
DOI: 10.3969/j.issn.2095-378X.2017.04.002
[1] Fisher B,Bryant J,Wolmark N,et al.Effect of preoperative chemotherapy on the outcome of women with operable breast cancer[J].J Clin Oncol,1998,16(8):2672-2785.
[2] Bear HD.Neoadjuvant chemotherapy for operable breast cancer:individualizing locoregional and systemic therapy[J].Surg Oncol Clin N Am,2010,19(3):607-626.
[3] Geng C,Chen X,Pan X.The feasibility and accuracy of sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy:a systematic review and meta-analysis[J].PLoS One,2016,11(9):e0162605.
[4] Mamounas EP,Brown A,Anderson S,et al.Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer:results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J].J Clin Oncol,2005,23(12):2694-2702.
[5] Boughey JC.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer[J].JAMA,2013,310(14):1455-1461.
[6] Boughey JC,Ballman KV,Hunt KK,et al.Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery:results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance)[J].J Clin Oncol,2015,33(30):3386-3393.
[7] Gradishar WJ,A.B.O.Balassanian R.Breast Cancer Version 2.2015[J].J Natl Compr Canc Netw,2015,33(3):448-475.
[8] Zetterlund LH,Frisell J,Zouzos A,et al.Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer[J].Breast Cancer Res Treat,2017,163(1):103-110.
[9] Boileau JF,Poirier B,Basik M,et al.Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer:the SN FNAC study[J].J Clin Oncol,2015,33(3):258-264.
[10] Kuehn T,Bauerfeind I,Fehm T,et al.Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA):a prospective,multicentre cohort study[J].Lancet Oncol,2013,14(7):609-618.
[11] Croshaw R,Shapiro-Wright H,Svensson E,et al.Accuracy of clinical examination,digital mammogram,ultrasound,and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients[J].Ann Surg Oncol,2011,18(11):3160-3163.
[12] Liu S,Ren R,Chen Z,et al.Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy[J].J Magn Reson Imaging,2015,42(3):779-787.
